|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
1997-1-15
|
|
pubmed:abstractText |
Etoposide, an inhibitor of the normal religation activity of the nuclear enzyme topoisomerase II, can induce a secondary acute myeloid leukemia characterized by site-specific DNA rearrangements. The schedule of drug administration appears to be a clinical risk factor for this devastating treatment complication.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
18
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1840-7
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8961974-Acute Disease,
pubmed-meshheading:8961974-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:8961974-Base Sequence,
pubmed-meshheading:8961974-DNA, Neoplasm,
pubmed-meshheading:8961974-DNA Primers,
pubmed-meshheading:8961974-Etoposide,
pubmed-meshheading:8961974-Exons,
pubmed-meshheading:8961974-Gene Rearrangement,
pubmed-meshheading:8961974-Humans,
pubmed-meshheading:8961974-Leukemia,
pubmed-meshheading:8961974-Leukemia, Myeloid,
pubmed-meshheading:8961974-Molecular Sequence Data,
pubmed-meshheading:8961974-Neoplasms, Second Primary,
pubmed-meshheading:8961974-Sequence Deletion,
pubmed-meshheading:8961974-Time Factors,
pubmed-meshheading:8961974-Tumor Cells, Cultured
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
|
|
pubmed:affiliation |
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38101-0318, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
